EA030478B1 - Применение биотина для лечения рассеянного склероза - Google Patents
Применение биотина для лечения рассеянного склероза Download PDFInfo
- Publication number
- EA030478B1 EA030478B1 EA201590270A EA201590270A EA030478B1 EA 030478 B1 EA030478 B1 EA 030478B1 EA 201590270 A EA201590270 A EA 201590270A EA 201590270 A EA201590270 A EA 201590270A EA 030478 B1 EA030478 B1 EA 030478B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- biotin
- multiple sclerosis
- treatment
- patient
- use according
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title claims abstract description 175
- 229960002685 biotin Drugs 0.000 title claims abstract description 87
- 235000020958 biotin Nutrition 0.000 title claims abstract description 87
- 239000011616 biotin Substances 0.000 title claims abstract description 87
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 53
- 238000011282 treatment Methods 0.000 title claims description 73
- 230000000750 progressive effect Effects 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 229960004979 fampridine Drugs 0.000 claims description 9
- 208000012902 Nervous system disease Diseases 0.000 claims description 8
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 6
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 229960000556 fingolimod Drugs 0.000 claims description 4
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 4
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 229960005027 natalizumab Drugs 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 3
- 102000003996 Interferon-beta Human genes 0.000 claims description 3
- 108090000467 Interferon-beta Proteins 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- 229960003776 glatiramer acetate Drugs 0.000 claims description 3
- 229940124622 immune-modulator drug Drugs 0.000 claims description 3
- 229960001388 interferon-beta Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 201000010099 disease Diseases 0.000 description 28
- 230000000007 visual effect Effects 0.000 description 24
- 230000004304 visual acuity Effects 0.000 description 21
- 230000006872 improvement Effects 0.000 description 19
- 208000006011 Stroke Diseases 0.000 description 15
- 230000006378 damage Effects 0.000 description 15
- 238000011161 development Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- 230000005713 exacerbation Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000003902 lesion Effects 0.000 description 10
- 238000001802 infusion Methods 0.000 description 9
- 210000001328 optic nerve Anatomy 0.000 description 9
- 210000000278 spinal cord Anatomy 0.000 description 9
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 8
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 8
- 210000003050 axon Anatomy 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 206010019452 Hemianopia Diseases 0.000 description 6
- 208000007460 Hemianopsia Diseases 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 206010053395 Progressive multiple sclerosis Diseases 0.000 description 6
- 206010039729 Scotoma Diseases 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 6
- 230000000763 evoking effect Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 208000003164 Diplopia Diseases 0.000 description 5
- 102000006386 Myelin Proteins Human genes 0.000 description 5
- 108010083674 Myelin Proteins Proteins 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 210000005012 myelin Anatomy 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 210000004885 white matter Anatomy 0.000 description 5
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229960004584 methylprednisolone Drugs 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229940087854 solu-medrol Drugs 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- 150000004669 very long chain fatty acids Chemical class 0.000 description 4
- 208000029257 vision disease Diseases 0.000 description 4
- 206010003591 Ataxia Diseases 0.000 description 3
- 208000015879 Cerebellar disease Diseases 0.000 description 3
- 206010008072 Cerebellar syndrome Diseases 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 108010005714 Interferon beta-1b Proteins 0.000 description 3
- 208000034800 Leukoencephalopathies Diseases 0.000 description 3
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 3
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 3
- 206010061323 Optic neuropathy Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 206010029864 nystagmus Diseases 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000008000 3-methylcrotonyl-CoA carboxylase deficiency Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-N CDP-choline Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-N 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010037714 Quadriplegia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940127530 Sphingosine 1-Phosphate Receptor Modulators Drugs 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 206010053648 Vascular occlusion Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 101150045969 abcD1 gene Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000029444 double vision Diseases 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000004171 ischemic cascade Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000000858 peroxisomal effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001373 regressive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 208000021331 vascular occlusion disease Diseases 0.000 description 2
- GJSFKOVNQYGUGN-JQVZGLFNSA-N (2E)-pentenoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)/C=C/CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 GJSFKOVNQYGUGN-JQVZGLFNSA-N 0.000 description 1
- 108700005389 3-methylcrotonyl CoA carboxylase 1 deficiency Proteins 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010008795 Chromatopsia Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010015727 Extensor plantar response Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- 102000006391 Ion Pumps Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010085747 Methylmalonyl-CoA Decarboxylase Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 1
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 1
- 208000002548 Spastic Paraparesis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 206010071434 biotinidase deficiency Diseases 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006327 debiotinylation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000005022 impaired gait Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 201000001801 internuclear ophthalmoplegia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 108010071806 methylcrotonoyl-CoA carboxylase Proteins 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000015010 neck weakness Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 208000028780 ocular motility disease Diseases 0.000 description 1
- 210000004398 oculomotor muscle Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000037118 sensory ataxia Diseases 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 150000003409 sphingosine 1-phosphates Chemical class 0.000 description 1
- 210000003009 spinothalamic tract Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1257254A FR2993780B1 (fr) | 2012-07-26 | 2012-07-26 | Methode de traitement de la sclerose en plaque |
| US13/644,615 US8835487B2 (en) | 2012-07-26 | 2012-10-04 | Method of treating multiple sclerosis |
| PCT/EP2013/058936 WO2014016003A1 (en) | 2012-07-26 | 2013-04-29 | Use of biotin for the treatment of multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201590270A1 EA201590270A1 (ru) | 2015-11-30 |
| EA030478B1 true EA030478B1 (ru) | 2018-08-31 |
Family
ID=47294963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590270A EA030478B1 (ru) | 2012-07-26 | 2013-04-29 | Применение биотина для лечения рассеянного склероза |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8835487B2 (enExample) |
| EP (2) | EP2729143B1 (enExample) |
| JP (1) | JP6208235B2 (enExample) |
| KR (1) | KR101967502B1 (enExample) |
| CN (2) | CN109908140A (enExample) |
| AU (1) | AU2013295370B2 (enExample) |
| BR (1) | BR112015001562A2 (enExample) |
| CA (1) | CA2879434C (enExample) |
| CY (1) | CY1116304T1 (enExample) |
| DK (2) | DK2729143T3 (enExample) |
| EA (1) | EA030478B1 (enExample) |
| ES (3) | ES2532364T3 (enExample) |
| FR (1) | FR2993780B1 (enExample) |
| HK (1) | HK1207583A1 (enExample) |
| HR (1) | HRP20150260T1 (enExample) |
| HU (1) | HUE024558T2 (enExample) |
| IL (1) | IL236790A (enExample) |
| LT (1) | LT2857019T (enExample) |
| ME (1) | ME02060B (enExample) |
| PL (1) | PL2729143T3 (enExample) |
| PT (2) | PT2729143E (enExample) |
| RS (1) | RS53893B1 (enExample) |
| SI (2) | SI2729143T1 (enExample) |
| SM (1) | SMT201500057B (enExample) |
| WO (1) | WO2014016003A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) * | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| WO2014177286A1 (en) | 2013-04-29 | 2014-11-06 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
| JP6108045B2 (ja) * | 2015-02-13 | 2017-04-05 | ユニマテック株式会社 | 含フッ素共重合体およびこれを有効成分とする表面改質剤 |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| US20170135969A1 (en) | 2015-11-12 | 2017-05-18 | Jds Therapeutics, Llc | Topical arginine-silicate-inositol for wound healing |
| WO2017086835A1 (ru) * | 2015-11-17 | 2017-05-26 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты) |
| RU2611415C1 (ru) * | 2015-11-17 | 2017-02-21 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты) |
| RU2638803C2 (ru) * | 2016-06-09 | 2017-12-15 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки биотина с замедленным высвобождением и способ их получения |
| EP3275439A1 (en) | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| AU2017318672B2 (en) * | 2016-09-01 | 2022-03-10 | Nutrition 21, Llc | Magnesium biotinate compositions and methods of use |
| RU2639488C1 (ru) * | 2017-04-06 | 2017-12-21 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Фармацевтическая композиция, содержащая биотин, и способ ее получения |
| WO2020102203A1 (en) * | 2018-11-13 | 2020-05-22 | Jds Therapeutics, Llc | Treatment of autoimmune disorders, such as relapsing remitting multiple sclerosis and clinically isolated syndrome with biotin compositions |
| CN112076310A (zh) * | 2019-06-14 | 2020-12-15 | 苏州融析生物科技有限公司 | 一种治疗多发性硬化的药物组合物及其制备 |
| IL294021A (en) | 2019-12-16 | 2022-08-01 | Nutrition 21 Llc | Methods of production of arginine-silicate complexes |
| CA3157712C (en) | 2020-01-01 | 2024-01-23 | Jotiram PALKAR | Synergistic nutritional compositions for enhancing atp efficiency |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0891719A1 (en) * | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
| RU2220142C2 (ru) * | 1999-01-19 | 2003-12-27 | Берингер Ингельхайм Фармасьютиклз, Инк. | Ароматические гетероциклические соединения как противовоспалительные средства |
| US20050075385A1 (en) * | 2003-09-08 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Substituted thienoimidazoles useful for disease treatment and prevention |
| BG66011B1 (bg) * | 2005-05-25 | 2010-10-29 | Райна Щонова | Състав от растителен произход |
| US20110229585A1 (en) * | 2003-12-31 | 2011-09-22 | Kaiser Jon D | Nutrient compositions and methods for enhanced effectiveness of the immune system |
| WO2011124571A1 (fr) * | 2010-04-06 | 2011-10-13 | Assistance Publique - Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3609165A (en) | 1968-07-19 | 1971-09-28 | Research Corp | 1,3-diazabicyclo {8 3.1.0{9 {0 hex-3-enes |
| JPH0995448A (ja) | 1995-09-29 | 1997-04-08 | Calpis Food Ind Co Ltd:The | 血中ビオチン濃度の増加方法およびビオチン含有飲食品 |
| US5789401A (en) | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
| US6664039B1 (en) | 1998-10-14 | 2003-12-16 | California Institute Of Technology | Methods and compositions for modulating neurodegeneration |
| DE19903241A1 (de) | 1999-01-28 | 2000-08-03 | Merck Patent Gmbh | Galenische Formulierung |
| AU2003266287A1 (en) | 2002-08-23 | 2004-03-11 | Dsm Ip Assets B.V. | Novel nutraceutical compositions comprising biotin |
| US7709028B2 (en) | 2002-09-30 | 2010-05-04 | Daiichi Pharmaceutical Co., Ltd. | Particulate product comprising pantethine |
| IL162288A0 (en) * | 2004-06-01 | 2005-11-20 | Future Products Man S A | Compositions and methods for treating neurodegenerative disorders |
| US20130004545A1 (en) | 2009-12-23 | 2013-01-03 | Lupin Limited | Slow release pharmaceutical compositions of iloperidone |
| FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
-
2012
- 2012-07-26 FR FR1257254A patent/FR2993780B1/fr not_active Expired - Fee Related
- 2012-10-04 US US13/644,615 patent/US8835487B2/en active Active
-
2013
- 2013-04-29 ES ES13719836.2T patent/ES2532364T3/es active Active
- 2013-04-29 PT PT13719836T patent/PT2729143E/pt unknown
- 2013-04-29 EA EA201590270A patent/EA030478B1/ru not_active IP Right Cessation
- 2013-04-29 RS RS20150168A patent/RS53893B1/sr unknown
- 2013-04-29 SI SI201330023T patent/SI2729143T1/sl unknown
- 2013-04-29 CA CA2879434A patent/CA2879434C/en not_active Expired - Fee Related
- 2013-04-29 DK DK13719836.2T patent/DK2729143T3/en active
- 2013-04-29 LT LTEP14194213.6T patent/LT2857019T/lt unknown
- 2013-04-29 AU AU2013295370A patent/AU2013295370B2/en not_active Ceased
- 2013-04-29 HU HUE13719836A patent/HUE024558T2/hu unknown
- 2013-04-29 CN CN201910026016.2A patent/CN109908140A/zh active Pending
- 2013-04-29 ES ES14194213T patent/ES2811074T3/es active Active
- 2013-04-29 HR HRP20150260TT patent/HRP20150260T1/hr unknown
- 2013-04-29 EP EP13719836.2A patent/EP2729143B1/en active Active
- 2013-04-29 WO PCT/EP2013/058936 patent/WO2014016003A1/en not_active Ceased
- 2013-04-29 BR BR112015001562A patent/BR112015001562A2/pt not_active Application Discontinuation
- 2013-04-29 SI SI201331768T patent/SI2857019T1/sl unknown
- 2013-04-29 ME MEP-2015-32A patent/ME02060B/me unknown
- 2013-04-29 PT PT141942136T patent/PT2857019T/pt unknown
- 2013-04-29 KR KR1020157004516A patent/KR101967502B1/ko not_active Expired - Fee Related
- 2013-04-29 PL PL13719836T patent/PL2729143T3/pl unknown
- 2013-04-29 EP EP14194213.6A patent/EP2857019B1/en active Active
- 2013-04-29 DK DK14194213.6T patent/DK2857019T3/da active
- 2013-04-29 HK HK15108330.5A patent/HK1207583A1/xx unknown
- 2013-04-29 CN CN201380039687.3A patent/CN104602689A/zh active Pending
- 2013-04-29 JP JP2015523453A patent/JP6208235B2/ja not_active Expired - Fee Related
-
2014
- 2014-01-14 ES ES14700423.8T patent/ES2626079T3/es active Active
- 2014-08-13 US US14/458,625 patent/US9351961B2/en not_active Expired - Fee Related
-
2015
- 2015-01-19 IL IL236790A patent/IL236790A/en active IP Right Grant
- 2015-03-09 SM SM201500057T patent/SMT201500057B/xx unknown
- 2015-03-11 CY CY20151100243T patent/CY1116304T1/el unknown
-
2016
- 2016-04-12 US US15/096,957 patent/US10201528B2/en not_active Expired - Fee Related
-
2018
- 2018-12-21 US US16/231,073 patent/US20190117625A1/en not_active Abandoned
- 2018-12-21 US US16/231,111 patent/US20190117626A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0891719A1 (en) * | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
| RU2220142C2 (ru) * | 1999-01-19 | 2003-12-27 | Берингер Ингельхайм Фармасьютиклз, Инк. | Ароматические гетероциклические соединения как противовоспалительные средства |
| US20050075385A1 (en) * | 2003-09-08 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Substituted thienoimidazoles useful for disease treatment and prevention |
| US20110229585A1 (en) * | 2003-12-31 | 2011-09-22 | Kaiser Jon D | Nutrient compositions and methods for enhanced effectiveness of the immune system |
| BG66011B1 (bg) * | 2005-05-25 | 2010-10-29 | Райна Щонова | Състав от растителен произход |
| WO2011124571A1 (fr) * | 2010-04-06 | 2011-10-13 | Assistance Publique - Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
Non-Patent Citations (7)
| Title |
|---|
| "Cerebrospinal fluid levels of biotin in various neurological disorders", 1 January 1999 (1999-01-01), pages 387-392, XP055064661, Retrieved from the Internet: URL:http://onlinelibrary.wiley.com/store/10.1111/j.1600-0404.1999.tb07369.x/asset/j.1600-0404.1999.tb07369.x.pdf?v=1&t=hhanuilw&s=8a3a28c642a4el4c7244312a0d97dbcf20126954 [retrieved on 2013-05-29], cited in the application, the whole document * |
| Cathy Breedon: "Nutrition Issues in Multiple Sclerosis", Aunt Cathy's Guide to Nutrition, 1 January 2009 (2009-01-01), pages 1-29, XP055048445, Retrieved from the Internet: URL:http://talwd.org/pdf/fwtexastour/Aunt C MS Handout pt version W REFS 09this.pdf [retrieved on 2012-12-20], page 12 * |
| DARIN, N. ANDERSEN, O. WIKLUND, L.M. HOLMGREN, D. HOLME, E.: "3-Methylcrotonyl-CoA Carboxylase Deficiency and Severe Multiple Sclerosis", PEDIATRIC NEUROLOGY., ELSEVIER SCIENCE., NL, vol. 36, no. 2, 31 January 2007 (2007-01-31), NL, pages 132 - 134, XP 005867283, ISSN: 0887-8994, DOI: 10.1016/j.pediatrneurol.2006.09.007 * |
| MERODIO M. et al., Distribution of albumin nanoparticles in animals induced with the experimental allergic encephalomyelitis. J. Drug. Target, 2000; 8(5): p. 289-303 (реферат) [он-лайн] [найдено 16.07.2015], Найдено из PubMed, PMID:11328657 * |
| S.M. KIMIAGAR M. MOHAMMAD SHIRAZI F.A. TALEBAN M. GHAFARPOOR: "Dietary supplementation in Iranian multiple sclerosis patients", JOURNAL OF MEDICAL SCIENCES, A N S I NETWORK, PK, vol. 7, no. 3, 1 April 2007 (2007-04-01), PK, pages 413 - 417, XP 002689602, ISSN: 1682-4474, DOI: 10.3923/jms.2007.413.417 * |
| YANG YANLING; LI CHAOYANG; QI ZHAOYUE; XIAO JIANGXI; ZHANG YAO; YAMAGUCHI SEIJI; HASEGAWA YUKI; TAGAMI YASUKO; JIANG YUWU; XIONG H: "Spinal cord demyelination associated with biotinidase deficiency in 3 Chinese patients", JOURNAL OF CHILD NEUROLOGY., DECKER, CA, vol. 22, no. 2, 1 February 2007 (2007-02-01), CA, pages 156 - 160, XP 008126453, ISSN: 0883-0738, DOI: 10.1177/0883073807300307 * |
| ЕВТУШЕНКО С.К. и др. Современные подходы к лечению рассеянного склероза: достижения, разочарования, надежды (II сообщение). Международный неврологический журнал, 2(6), 2006, [он-лайн] [найдено 17.07.2015]. Найдено из Интернет: URL:http://www.mif-ua.com/archive/issue-2551>, глава "Профилактика нейродегенерации" * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013295370B2 (en) | Use of biotin for the treatment of multiple sclerosis | |
| JP5212849B2 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| US20190314342A1 (en) | Method for treating demyelinating neuropathy with biotin | |
| US20190134006A1 (en) | Method of treating multiple sclerosis | |
| HK40008598A (en) | Use of biotin for the treatment of multiple sclerosis | |
| US8664209B2 (en) | Daptomycin for multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KZ KG TJ TM |